Introduction
NAFLD, Obesity, cirrhosis, liver diseasesThis disease, obese liver disease, metabolic syndrome, weight loss, heart and liver diseases
OBESITY, CIRRHOSIS, NON-ALCOHOLIC FATTY LIVER DISEASE, HYPERGLYCEMIA, INSULIN RESISTANCE, HEPATIC STEATOSIS, METABOLIC SYNDROME, HIGH BLOOD PRESSURE, INSULIN SENSITIVITY
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseasesThis disease is significant due to the destruction of liver cells, which can progress to cirrhosis, where liver transplantation is the only treatmentInsulin resistance is a known cardiovascular risk factor. Physical activity reduces insulin resistance by enhancing insulin sensitivity in skeletal muscle and decreasing hepatic steatosis. Furthermore, physical activity increases energy expenditure. This can result in weight loss and a reduction in intrahepatic triglyceride levels. In addition, the benefits of physical activity have been demonstrated in patients with obese liver disease who are at risk for cardiovascular diseaseFunctional resistance training has been a part of the training program in some treatment methods for chronic heart and liver diseases. These exercises were previously used for therapeutic effects on metabolic syndrome and have had positive results in indicators of, Obesity, hyperglycemia, high blood pressure, and hypertriglyceridemiaFunctional training is gaining popularity in the fitness industry and is regarded as a superior alternative to conventional resistance training for enhancing various measures of muscular fitness, such as strength, endurance, coordination, and balanceThe cardiovascular system induced a significant adaptation to sports training. The most important of these adaptations include changes in the cardiovascular system's structural cellular and molecular signaling pathways that allow tissues to respond to the physical demands created by exerciseConsequently, this study aims to determine the effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver disease.